Koeleria Macrantha Pollen

Dosage for Koeleria Macrantha Pollen is highly individualized and must be determined by a qualified allergist based on the patient's sensitivity levels. There is no 'standard' dose, as the extract is non-standardized.

Buildup Phase

The buildup phase typically involves weekly or bi-weekly injections. The starting dose is usually very low, often ranging from 0.05 mL of a 1:100,000 w/v or 1:10,000 w/v dilution. The dose is incrementally increased (e.g., 0.1 mL, 0.2 mL, 0.3 mL) at each visit, provided the patient tolerates the previous dose without significant local or systemic reactions.

Maintenance Phase

Once the 'top dose' or maintenance dose is reached—which might be 0.5 mL of a 1:100 w/v or 1:20 w/v concentration—the interval between injections is increased. Maintenance injections are typically administered every 2 to 4 weeks. The goal is to maintain the highest dose the patient can tolerate without adverse effects for a period of 3 to 5 years.

Koeleria Macrantha Pollen is used in children, generally starting around age 5. Younger children may be treated if the clinical need is significant and the child can cooperate with the injection and observation process. Dosing protocols for children are similar to adults, though the physician may exercise more caution during the buildup phase. Safety and efficacy in children under age 5 have not been extensively established in large-scale clinical trials.

Renal Impairment

No dosage adjustments are typically required for patients with renal impairment, as the proteins are not cleared via the kidneys. However, the patient's overall health and ability to tolerate a systemic reaction must be considered.

Hepatic Impairment

No adjustments are necessary for hepatic impairment. The metabolism of allergenic proteins is independent of the cytochrome P450 system.

Elderly Patients

Elderly patients (over 65) require careful evaluation. The primary concern is the presence of underlying cardiovascular disease, which could make the use of epinephrine (the treatment for a severe allergic reaction) more dangerous. The physician may opt for a more conservative buildup schedule.

1. 1Administration: This medication is administered via subcutaneous injection, usually in the posterior aspect of the upper arm. It must NEVER be injected intravenously.
2. 2Observation: Patients MUST remain in the medical office for at least 30 minutes following each injection. Most fatal or near-fatal reactions occur within this window.
3. 3Timing: Injections should be scheduled at consistent intervals. If a patient is ill with a fever or experiencing an asthma flare-up, the injection should be postponed.
4. 4Storage: Vials must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). They should not be frozen. Exposure to heat or light can degrade the proteins and reduce efficacy.

If a dose is missed, the next dose may need to be reduced depending on how much time has passed.

• 1-2 weeks late: Often the same dose can be given.
• 3-4 weeks late: The dose may be reduced to the previous level.
• Over 4 weeks late: A significant reduction in dose or restarting the buildup may be necessary to prevent a systemic reaction.

An 'overdose' in the context of immunotherapy occurs if a dose is administered that exceeds the patient's current tolerance level. This can lead to a severe systemic reaction or anaphylaxis.

• Signs: Hives (urticaria), swelling of the throat (angioedema), wheezing, shortness of breath, rapid heart rate, or a drop in blood pressure.
• Emergency Measures: Immediate administration of epinephrine, followed by antihistamines, corticosteroids, and emergency medical transport. Patients should be monitored for several hours for 'biphasic' reactions.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not attempt to self-administer these injections unless specifically trained and authorized in a home-use program (which is rare for SCIT).

Most patients undergoing immunotherapy with Koeleria Macrantha Pollen will experience some form of local reaction. These are generally not dangerous but can be uncomfortable.

• Injection Site Redness (Erythema): A red patch at the site of the shot, usually appearing within minutes and resolving within 24 hours.
• Swelling (Edema): A raised bump or 'wheal' at the injection site. If the swelling is larger than a half-dollar (approx. 3-5 cm), it may indicate the need to adjust the next dose.
• Itching (Pruritus): Localized itching at the site of administration.
• Tenderness: The arm may feel slightly sore or heavy for a few hours after the injection.

These reactions are more systemic in nature and require close monitoring by your doctor.

• Generalized Itching: Itching that occurs away from the injection site.
• Mild Hives: A few scattered hives (urticaria) on the body.
• Nasal Congestion: A 'stuffy' feeling or sneezing shortly after the injection.
• Fatigue: Some patients report feeling unusually tired for the remainder of the day after their shot.

These are significant reactions that may require a pause or modification of treatment.

• Persistent Cough: A dry, hacking cough shortly after the injection.
• Mild Wheezing: Slight chest tightness or audible whistling when breathing.
• Gastrointestinal Upset: Nausea or abdominal cramping, which can sometimes be a precursor to a more severe systemic reaction.

> Warning: Stop taking Koeleria Macrantha Pollen and call your doctor immediately or seek emergency care if you experience any of these symptoms of anaphylaxis.

• Anaphylaxis: A life-threatening, whole-body allergic reaction. Symptoms include a sudden drop in blood pressure (fainting, dizziness), rapid or weak pulse, and loss of consciousness.
• Angioedema: Severe swelling of the lips, tongue, or throat that can obstruct the airway.
• Severe Bronchospasm: Intense wheezing and inability to catch one's breath, often requiring emergency bronchodilators.
• Cyanosis: A bluish tint to the lips or fingernails, indicating a lack of oxygen.
• Uterine Contractions: In rare cases, systemic allergic reactions can trigger uterine cramping in pregnant women.

There are no known long-term 'toxic' effects of Koeleria Macrantha Pollen, as it is a natural protein extract. However, the primary long-term risk is the development of new sensitivities or the rare possibility of 'serum sickness,' though this is extremely uncommon with modern, purified extracts. Most patients find that the long-term benefit of reduced allergy symptoms far outweighs the risks of the treatment.

While Koeleria Macrantha Pollen extracts do not always carry a specific 'Black Box' in the same way as some pharmaceutical drugs, they are subject to the general FDA warning for all allergenic extracts regarding the risk of severe systemic reactions.

FDA Warning Summary: Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis. They should only be administered by healthcare providers prepared to manage such reactions. Patients with unstable asthma are at a higher risk for fatal outcomes. Healthcare providers must observe patients for at least 30 minutes post-injection.

Report any unusual symptoms or delayed reactions (occurring hours after the shot) to your healthcare provider immediately.

Koeleria Macrantha Pollen immunotherapy is a biological treatment that carries the inherent risk of triggering the very allergic symptoms it is intended to treat. Patients must be fully informed of the risks and benefits before beginning therapy. It is essential that patients are capable of recognizing the early signs of a systemic reaction and have access to emergency medical care.

No specific 'Black Box' warning is unique to Koeleria Macrantha Pollen; however, the FDA requires all allergenic extracts to include a prominent warning regarding the risk of anaphylaxis. This warning emphasizes that injections should only be given in a clinical setting equipped with emergency supplies, including oxygen, IV fluids, and epinephrine.

• Allergic Reactions / Anaphylaxis Risk: This is the primary concern. Risk factors for severe reactions include a high level of sensitivity (as shown on skin tests), the buildup phase of treatment, and the use of high-potency extracts.
• Asthma Status: Patients with uncontrolled or severe asthma are at a significantly higher risk for a fatal reaction if they experience anaphylaxis. Asthma must be stable and well-controlled before an injection is administered.
• Beta-Blocker Use: Patients taking beta-blockers (for high blood pressure or heart conditions) may be resistant to the effects of epinephrine, making a systemic reaction much harder to treat. This is often considered a relative contraindication.
• Infection and Illness: If a patient has a viral infection, fever, or is experiencing a 'flare-up' of their usual allergy symptoms, the immune system is already 'primed.' Administering an injection during this time increases the risk of a systemic reaction.

• 30-Minute Observation: Every patient must be monitored in the clinic for 30 minutes post-injection. No exceptions.
• Peak Flow Monitoring: For patients with asthma, the doctor may require a peak flow meter test before the injection to ensure lung function is at its baseline.
• Injection Site Check: The nurse or doctor will check the injection site for large local reactions before the patient leaves and before the next dose is given.
• Annual Review: Patients should have an annual review with their allergist to assess the efficacy of the treatment and determine if the maintenance dose needs adjustment.

In general, Koeleria Macrantha Pollen does not cause drowsiness or cognitive impairment. However, if a patient experiences a systemic reaction or feels faint after an injection, they should not drive until they are fully recovered and cleared by a medical professional.

There is no direct chemical interaction between alcohol and the pollen extract. However, alcohol can cause vasodilation (widening of blood vessels), which may theoretically increase the speed of allergen absorption or worsen the symptoms of a systemic reaction. It is generally advised to avoid heavy alcohol consumption on the day of an injection.

Immunotherapy is typically discontinued after 3 to 5 years of successful maintenance. There is no 'withdrawal' syndrome associated with stopping the injections, but the patient's allergy symptoms may eventually return over several years. If treatment is stopped prematurely during the buildup phase, the clinical benefits will likely be lost.

> Important: Discuss all your medical conditions, especially heart or lung problems, with your healthcare provider before starting Koeleria Macrantha Pollen.

There are few absolute contraindications for drug combinations, but the following are highly discouraged:

• Beta-Blockers (Non-Selective): Drugs like propranolol or nadolol can block the effects of epinephrine. If a patient on these drugs has an anaphylactic reaction to the pollen extract, the standard emergency treatment may fail. This can lead to fatal outcomes.

• ACE Inhibitors: Some studies suggest that patients taking ACE inhibitors (like lisinopril) may be at a higher risk for more severe systemic reactions, possibly due to the drug's effect on the kinin system.
• MAO Inhibitors (MAOIs): These drugs can potentiate the effects of sympathomimetic amines (like epinephrine), potentially leading to a hypertensive crisis if epinephrine must be used to treat a reaction.
• Tricyclic Antidepressants: Similar to MAOIs, these can interfere with the metabolism of emergency medications used during a reaction.

• Antihistamines: While not dangerous, taking antihistamines (like loratadine or cetirizine) can mask the early 'warning signs' of a systemic reaction, such as mild itching or sneezing. This might lead the healthcare provider to increase the dose too quickly.
• Oral Steroids: Chronic use of oral prednisone may suppress the immune response, potentially making the immunotherapy less effective, though it does not usually pose a safety risk.

There are no known direct food interactions with Koeleria Macrantha Pollen. However, patients with 'Oral Allergy Syndrome' (OAS) may experience cross-reactivity. People allergic to June Grass may find that certain foods (like melons, oranges, or tomatoes) cause itching in the mouth. This is not a drug interaction but a feature of the underlying allergy.

• St. John's Wort: No known interaction.
• Immunostimulants (e.g., Echinacea): Theoretically, supplements that claim to 'boost' the immune system could interfere with the desensitization process, which aims to 'calm' a specific part of the immune response. Patients should disclose all supplement use to their allergist.

• Skin Testing: If a patient is receiving Koeleria Macrantha Pollen immunotherapy, their skin test reactivity to that specific grass will likely decrease over time. This is a sign of treatment success rather than a 'false' result.
• Serum IgE/IgG4: Immunotherapy will cause a rise in grass-specific IgG4 levels and a temporary rise followed by a long-term fall in specific IgE levels. These are expected clinical markers.

For each major interaction, the primary concern is not a chemical reaction between the substances, but rather an interference with the body's ability to respond to or survive a systemic allergic reaction (anaphylaxis).

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any medications for blood pressure, heart rhythm, or depression.

Koeleria Macrantha Pollen must NEVER be used in the following circumstances:

1. 1Severe, Uncontrolled Asthma: Patients whose asthma is not well-managed with standard medications are at an extremely high risk of death if they experience a systemic reaction to an injection.
2. 2Recent Myocardial Infarction or Unstable Angina: The physiological stress of a systemic reaction, or the epinephrine required to treat it, could trigger a second heart attack.
3. 3History of Severe Reaction to This Specific Extract: If a patient has previously experienced a near-fatal reaction to June Grass extract, the risks of continuing therapy usually outweigh the benefits.
4. 4Inability to Use Epinephrine: If a patient has a medical condition that makes the use of an epinephrine auto-injector impossible or extremely dangerous, they should not receive SCIT.

These conditions require a careful risk-benefit analysis by the allergist:

• Autoimmune Disorders: There is a theoretical concern that stimulating the immune system with extracts could worsen conditions like systemic lupus erythematosus (SLE) or rheumatoid arthritis, though evidence for this is limited.
• Malignancy: Patients with active cancer may have altered immune systems, making the response to immunotherapy unpredictable.
• Severe Atopic Dermatitis: In some cases, immunotherapy can cause a temporary flare-up of eczema symptoms.
• Beta-Blocker Therapy: As mentioned, this makes treating a reaction more difficult.

Patients allergic to Koeleria Macrantha Pollen are almost always cross-sensitive to other members of the Poaceae family (grasses). This includes:

• Timothy Grass (Phleum pratense)
• Orchard Grass (Dactylis glomerata)
• Kentucky Bluegrass (Poa pratensis)
• Perennial Rye Grass (Lolium perenne)

Because of this high degree of cross-reactivity, many allergists use a 'Grass Mix' extract rather than June Grass alone.

> Important: Your healthcare provider will evaluate your complete medical history, including your lung function and heart health, before prescribing Koeleria Macrantha Pollen.

FDA Pregnancy Category: Not formally assigned (often considered Category C).

• Risk Summary: There is no evidence that Koeleria Macrantha Pollen is teratogenic (causes birth defects). However, the primary risk to the fetus is maternal anaphylaxis, which can cause uterine contractions and fetal hypoxia (lack of oxygen).
• Clinical Practice: Allergists generally do NOT start a new course of immunotherapy during pregnancy because the risk of a reaction is highest during the buildup phase. However, if a woman is already on a stable maintenance dose and is tolerating it well, the treatment is usually continued throughout pregnancy to prevent a surge in allergy symptoms.

It is generally considered safe to continue Koeleria Macrantha Pollen immunotherapy while breastfeeding. The allergenic proteins are broken down in the mother's tissues and do not pass into breast milk in any significant or harmful amount. The benefits of the mother having controlled allergy symptoms usually outweigh any theoretical risks to the nursing infant.

• Approved Age: Immunotherapy is commonly used in children aged 5 and older.
• Considerations: Children are at the same risk for systemic reactions as adults. The decision to start therapy depends on the severity of the child's symptoms and their ability to tolerate the injections and the 30-minute wait time. Some studies suggest that early immunotherapy in children may prevent the development of asthma later in life (the 'allergic march').

Patients over age 65 may be at higher risk for complications from immunotherapy, primarily due to co-existing cardiovascular or pulmonary diseases.

• Cardiovascular Risk: The heart may not tolerate the stress of a systemic reaction or the administration of epinephrine.
• Polypharmacy: Older patients are more likely to be on medications like beta-blockers or ACE inhibitors that complicate allergy treatment.

There are no specific guidelines for renal impairment. Since the extract is composed of proteins that are degraded locally and systemically by proteases, renal function does not significantly impact the clearance or safety of the drug.

There are no specific guidelines for hepatic impairment. The liver does not play a primary role in the metabolism of injected allergenic extracts.

> Important: Special populations require an individualized assessment. Pregnant women and the elderly should have a detailed discussion with their allergist regarding the safety of continuing or starting therapy.

Koeleria Macrantha Pollen extract works through 'Allergen-Specific Immunotherapy' (ASIT). The molecular goal is to induce 'peripheral tolerance.' This involves the induction of regulatory T cells (Tregs) that produce IL-10. IL-10 is a potent anti-inflammatory cytokine that suppresses IgE production and increases the production of IgG4. IgG4 acts as a 'decoy' antibody, binding to the June Grass pollen proteins before they can reach the IgE antibodies attached to mast cells. This prevents the release of histamine and other mediators of the allergic response.

• Dose-Response: There is a clear dose-response relationship in immunotherapy; higher doses (within the maintenance range) are generally more effective than lower doses, but they also carry a higher risk of side effects.
• Onset of Effect: Clinical improvement is not immediate. It typically takes 6 to 12 months of treatment before a patient notices a reduction in seasonal symptoms.
• Duration of Effect: After a full 3-5 year course, the 'immunological memory' can provide relief for several years, and in some cases, the effect is permanent.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous Injection) |

| Protein Binding | Primarily interacts with IgE/IgG antibodies |

| Half-life | Proteins are degraded within hours/days at the site |

| Tmax | Local immune interaction begins within minutes |

| Metabolism | Proteolysis by tissue enzymes |

| Excretion | Not renally or fecally excreted in intact form |

• Composition: A complex mixture of proteins, glycoproteins, and polysaccharides derived from the pollen of Koeleria macrantha.
• Major Allergens: Like other grasses, June Grass contains Group 1 and Group 5 allergens, which are the primary proteins responsible for IgE binding.
• Solubility: Highly soluble in aqueous buffered solutions.

Koeleria Macrantha Pollen is classified as a Non-Standardized Pollen Allergenic Extract. It belongs to the broader therapeutic category of 'Biologicals, Antigenic Extracts.' It is related to other grass extracts like Timothy, Orchard, and Sweet Vernal grass, which are often used together in poly-sensitized patients.